文献速递流行病学与生物统计临床试验与 GCP

急诊科丙型肝炎筛查:DETECT Hep C 随机临床试验

Hepatitis C Screening in Emergency Departments: The DETECT Hep C Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01

这项前瞻性、多中心、实用性随机临床试验在3个城市急诊科比较非靶向与靶向丙型肝炎筛查,共随机147498次就诊。非靶向筛查组新诊断154例,靶向筛查组115例,非靶向筛查显著更多(RR 1.34,95%CI 1.05-1.70;P=0.02)。从诊断到SVR12的留存比例大幅下降,作者认为亟需创新治疗模式。

要点

  • 非靶向筛查较靶向筛查检出更多新发HCV感染(RR 1.34,95%CI 1.05-1.70;P=0.02)。
  • 非靶向组13.4%接受检测并新诊断154例,靶向组6.3%检测并新诊断115例。
  • 新诊断者中非靶向组与靶向组分别有9.1%与9.6%达到SVR12。

核心结论

  • 在3个城市急诊科就诊患者中,非靶向筛查策略在识别新发HCV感染方面优于靶向筛查策略。
  • 从诊断到达到SVR12的患者大幅减少,作者认为亟需创新的HCV治疗模式。

研究设计与样本

  • 前瞻性、多中心、实用性随机临床试验,在科罗拉多州丹佛、马里兰州巴尔的摩和密西西比州杰克逊的3个城市急诊科开展。
  • 纳入18岁及以上患者,排除危重疾病、无法提供知情同意或既往已诊断HCV者。
  • 共随机147498次患者就诊(中位[IQR]年龄41[29-57]岁;51.5%男性;42.3%黑人、20.9%西班牙裔、32.2%白人)。
  • 患者随机接受非靶向筛查(无论风险均提供HCV检测)或靶向筛查(基于风险评估提供检测)。
  • 分析于2025年1月至3月按意向性治疗进行,使用相对危险度(RR)及95%CI和Fisher精确检验。

主要发现

  • 非靶向筛查组73847例患者中9867例(13.4%)接受HCV检测,新诊断154例。
  • 靶向筛查组73651例患者中23400例(31.8%)被识别有HCV感染危险因素,4640例(6.3%)接受检测,新诊断115例。
  • 非靶向筛查较靶向筛查识别显著更多新发HCV感染(RR 1.34 [95%CI 1.05-1.70];P=0.02)。
  • 新诊断患者中,非靶向组与靶向组分别有19.5%与24.3%链接至随访照护、15.6%与17.4%启动直接抗病毒药物(DAA)治疗、12.3%与12.2%完成DAA治疗、9.1%与9.6%达到12周持续病毒学应答(SVR12)。

关键数值与推荐

  • 主要结局为新诊断HCV感染(检测到RNA)。
  • 次要结局包括重复HCV诊断、HCV检测提供、接受与完成情况、HCV基因型与纤维化分期、HCV照护连续体各环节及18个月随访期间全因死亡率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Identification of individuals with hepatitis C virus (HCV) infection is a public health priority. Emergency departments (EDs) have been a focus of screening efforts, as they serve large numbers of at-risk patients who commonly do not access health care elsewhere. However, the optimal approach to HCV screening in ED settings remains unknown. OBJECTIVE: To evaluate the effectiveness of HCV screening in EDs with the hypothesis that nontargeted screening identifies more new diagnoses than targeted screening. DESIGN, SETTING, AND PARTICIPANTS: Prospective, multicenter, pragmatic randomized clinical trial performed at 3 urban EDs in Denver, Colorado; Baltimore, Maryland; and Jackson, Mississippi. Patients were 18 years or older, with exclusions for critical illness, inability to provide consent, or previously diagnosed HCV. INTERVENTIONS: As part of routine ED care, patients were randomly assigned to undergo either nontargeted screening, in which HCV testing was offered regardless of risk, or targeted screening, in which testing was offered based on risk assessment. MAIN OUTCOMES AND MEASURES: The primary outcome was newly diagnosed HCV infection (RNA detected). Secondary outcomes were repeat HCV diagnoses; HCV test offer, acceptance, and completion; HCV genotype and fibrosis staging; components of the HCV care continuum; and all-cause mortality through 18 months of follow-up. Analyses were conducted from January to March 2025 by intention-to-treat analysis, using relative risk (RR) with 95% CIs and Fisher exact tests. RESULTS: A total of 147 498 patient visits were randomized (median [IQR] age, 41 [29-57] years; 51.5% male; and 42.3% Black, 20.9% Hispanic, and 32.2% White). Of these, 73 847 patients underwent nontargeted screening, resulting in 9867 (13.4%) tested for HCV and 154 new HCV diagnoses, whereas 73 651 patients underwent targeted screening and 23 400 (31.8%) were identified to have risk factors for HCV infection, resulting in 4640 (6.3%) patients tested for HCV and 115 new HCV diagnoses. Compared with targeted HCV screening, nontargeted HCV screening identified significantly more new diagnoses of HCV infection (RR, 1.34 [95% CI, 1.05-1.70]; P = .02). Among patients newly diagnosed with HCV infection, small proportions from the nontargeted and targeted screening groups were linked to follow-up care (19.5% vs 24.3%, respectively), initiated direct-acting antiviral (DAA) treatment (15.6% vs 17.4%), completed DAA treatment (12.3% vs 12.2%), and attained sustained virologic response at 12 weeks (SVR12) (9.1% vs 9.6%). CONCLUSIONS AND RELEVANCE: In this multicenter randomized clinical trial, a nontargeted screening approach was superior to targeted screening for identifying new HCV infections among patients seen in 3 urban EDs. The substantial decrease in patients who went from diagnosis to SVR12 highlights an urgent need for innovative models of HCV treatment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04003454.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Haukoos J, Rothman RE, Galbraith JW, et al. Hepatitis C Screening in Emergency Departments: The DETECT Hep C Randomized Clinical Trial. JAMA. 2025. PMID: 40632510. doi:10.1001/jama.2025.10563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。